Cargando…

COVID-19 and Parkinson’s Disease: What Do We Know So Far?

BACKGROUND: Many studies on Parkinson’s disease (PD) patients affected by Coronavirus-disease-2019 (COVID-19) were recently published. However, the small sample size of infected patients enrolled in most studies did not allow to draw robust conclusions on the COVID-19 impact in PD. OBJECTIVE: We aim...

Descripción completa

Detalles Bibliográficos
Autores principales:	Artusi, Carlo Alberto, Romagnolo, Alberto, Ledda, Claudia, Zibetti, Maurizio, Rizzone, Mario Giorgio, Montanaro, Elisa, Bozzali, Marco, Lopiano, Leonardo
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	IOS Press 2021
Materias:	Review
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8150504/ https://www.ncbi.nlm.nih.gov/pubmed/33749619 http://dx.doi.org/10.3233/JPD-202463

Ejemplares similares

SARS-CoV-2 vaccination, Parkinson’s disease, and other movement disorders: case series and short literature review
por: Imbalzano, Gabriele, et al.
Publicado: (2022)

Anxiety, depression, and worries in advanced Parkinson disease during COVID-19 pandemic
por: Montanaro, Elisa, et al.
Publicado: (2021)

Association between sleep disorders and cognitive dysfunctions in non-demented patients with advanced Parkinson’s disease
por: Montanaro, Elisa, et al.
Publicado: (2021)

Burden of caregiving for cardiovascular dysautonomia in Parkinson’s disease
por: Ledda, Claudia, et al.
Publicado: (2022)

COVID-19 in Parkinson's disease: Report on prevalence and outcome
por: Artusi, Carlo Alberto, et al.
Publicado: (2020)

Pisa Syndrome in Parkinson's Disease Is Associated With Specific Cognitive Alterations
por: Artusi, Carlo Alberto, et al.
Publicado: (2019)

Deep Brain Stimulation Outcomes in Parkinson's Disease Patients with Cognitive Impairment: Implications and Considerations
por: Romagnolo, Alberto, et al.
Publicado: (2023)

Cohort study of neurological comorbidities and COVID-19-related case fatality
por: Imbalzano, Gabriele, et al.
Publicado: (2021)

Neurological comorbidities and COVID-19-related case fatality: A cohort study
por: Romagnolo, Alberto, et al.
Publicado: (2021)

Neurological comorbidity and severity of COVID-19
por: Romagnolo, Alberto, et al.
Publicado: (2020)

Early reversible leukoencephalopathy and unilateral sixth cranial nerve palsy in mild COVID-19 infection
por: Piazza, Federico, et al.
Publicado: (2021)

Focal seizures with impaired awareness as long-term neurological complication of COVID-19: a case report
por: Bozzali, Marco, et al.
Publicado: (2021)

Onset of Covid-19 with impaired consciousness and ataxia: a case report
por: Balestrino, R., et al.
Publicado: (2020)

Role of the Cingulate Cortex in Dyskinesias-Reduced-Self-Awareness: An fMRI Study on Parkinson’s Disease Patients
por: Palermo, Sara, et al.
Publicado: (2018)

Should we offer deep brain stimulation to Parkinson’s disease patients with GBA mutations?
por: Artusi, Carlo Alberto, et al.
Publicado: (2023)

How resistant are levodopa‐resistant axial symptoms? Response of freezing, posture, and voice to increasing levodopa intestinal infusion rates in Parkinson disease
por: Imbalzano, Gabriele, et al.
Publicado: (2022)

Time to onset and duration of botulinum toxin efficacy in movement disorders
por: Ledda, Claudia, et al.
Publicado: (2022)

What we know so far
Publicado: (2021)

Amyloidogenesis: What Do We Know So Far?
por: Alraawi, Zeina, et al.
Publicado: (2022)

Neuropsychiatric Consequences of COVID-19: What Do We Know So Far?
por: Machado, Sergio, et al.
Publicado: (2022)

Diet in the Treatment of Epilepsy: What We Know So Far
por: Verrotti, Alberto, et al.
Publicado: (2020)

Anabaenopeptins: What We Know So Far
por: Monteiro, Patrick Romano, et al.
Publicado: (2021)

Neuroproteomics in Epilepsy: What Do We Know so Far?
por: do Canto, Amanda M., et al.
Publicado: (2021)

Eosinophilic Esophagitis—What Do We Know So Far?
por: Wąsik, Jakub, et al.
Publicado: (2023)

HIV and neoplasms: What do we know so far?
por: de Souza, Thais Faria, et al.
Publicado: (2023)

Fibrocartilaginous dysplasia: What do we know so far?
por: Alshalan, Asma, et al.
Publicado: (2023)

Dietary Restriction against Parkinson’s Disease: What We Know So Far
por: Wang, Zhonglei, et al.
Publicado: (2022)

Ketogenic Diet and Epilepsy: What We Know So Far
por: D’Andrea Meira, Isabella, et al.
Publicado: (2019)

The effects of huntingtin-lowering: what do we know so far?
por: Kaemmerer, William F, et al.
Publicado: (2019)

COVID-19 and Hematology—What Do We Know So Far?
por: Khandait, Harshwardhan, et al.
Publicado: (2020)

COVID-19 and Myocarditis: What Do We Know So Far?
por: Pirzada, Ashar, et al.
Publicado: (2020)

Electronic Cigarettes and Asthma: What Do We Know So Far?
por: Kotoulas, Serafeim-Chrysovalantis, et al.
Publicado: (2021)

COVID-19 and dizziness: What do we know so far?
por: Mezzalira, Raquel
Publicado: (2022)

Atherosclerosis in HIV Patients: What Do We Know so Far?
por: Poznyak, Anastasia V., et al.
Publicado: (2022)

COVID-19 and the liver: What do we know so far?
por: Nasa, Prashant, et al.
Publicado: (2021)

The cognitive effects of esketamine: what do we know so far?
por: Barbosa, M., et al.
Publicado: (2022)

Lisfranc Sports Injuries: What Do We Know So Far?
por: Maduka, Godsfavour C, et al.
Publicado: (2023)

Deep Brain Stimulation Selection Criteria for Parkinson’s Disease: Time to Go beyond CAPSIT-PD
por: Artusi, Carlo Alberto, et al.
Publicado: (2020)

Autoimmune pancreatitis: What we know so far
por: Masood, Muaaz
Publicado: (2021)

Incremental Hemodialysis: What We Know so Far
por: Soi, Vivek, et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_fdplrs5ik6e9os5cl9ck6cmj8t